Clinical trials: Eclampsia, Antepartum
Severe Preeclampsia
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
- Trial name
- NCT03008616
- Testing
- AMAG-423 (digoxin immune fab)
- Where
- 18 sites in United States, Poland and 1 more
- Volunteers
- 58 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Pre-Eclampsia, Hypertension in Pregnancy
Furosemide vs. Placebo for Severe Antepartum Hypertension
Primary objective: To determine whether the addition of intravenous furosemide with usual antihypertensives is associated with a reduction in mean systolic blood pressure from baseline compared to treatment with placebo plus…
- Conditions
- Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
- Trial name
- NCT04615624
- Testing
- Furosemide
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Melanie Maykin, MD
Pre-eclampsia
Efficacy Study of Digibind for Treatment of Severe Preeclampsia
The purpose of this study is to determine whether a commercially available anti-digoxin antibody, Digibind, can delay delivery in patients with severe pre-eclampsia.
- Trial name
- NCT00158743
- Testing
- Anti-digoxin antibody (FAB fragment), sodium chloride
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- BTG International Inc.